Skip to Content

High Throughput Drug Screening of FDA Approved Drugs for Glioblastoma Multiforme

Glioblastoma multiforme is a common treatment-resistant brain tumor with poor prognosis. GBM tumors resected at the University of Colorado Hospital were cultured in a brain-like matrix until confluent. Drug screening was done in triplicate using the National Cancer Institute’s anticancer library of already FDA approved drugs. Cell viability was then assessed. Carfilzomib, a proteasome inhibitor, was the most effective compound in the study and yielded an average cell viability of 40%. Carfilzomib remained the most effective compound for every tumor pathology or patient history subgroup investigated. FDA-approved drugs have potential as novel GBM therapies.

View Prezi